IFNB1 and myeloid sarcoma: Furthermore, Schulz et al. (2004) demonstrated that a 30 min endurance test in trained MS patients (immunomodulatory treatment included IFN-β and copaxone) who have undertaken an 8-week aerobic training programme (cycle ergometry at 60% of VO2max; 2 times/week) marginally enhanced levels of soluble IL-6 receptor (sIL-6R) in plasma (Schulz et al., 2004).